Pieris Pharmaceuticals - PIRS Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$1.15
▲ +0.04 (3.60%)

This chart shows the closing price for PIRS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Pieris Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PIRS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PIRS

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Pieris Pharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $1.15.

This chart shows the closing price for PIRS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Pieris Pharmaceuticals. This rating has held steady since June 2022, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/6/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/5/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/3/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/1/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/1/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/30/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/29/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/28/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/2/2021William BlairReiterated RatingBuyN/A
6/30/2021Jefferies Financial GroupBoost TargetBuy$6.00 ➝ $8.00Low
4/26/2021HC WainwrightReiterated RatingBuy$9.00High
3/30/2021HC WainwrightReiterated RatingBuy$9.00Medium
8/10/2020HC WainwrightReiterated RatingBuyLow
8/9/2020William BlairReiterated RatingOutperformHigh
7/23/2020HC WainwrightReiterated RatingBuyMedium
3/13/2020Robert W. BairdUpgradeNeutral ➝ Outperform$5.00High
1/27/2020HC WainwrightBoost TargetBuy$7.00 ➝ $9.00Low
11/11/2019William BlairReiterated RatingBuyHigh
11/11/2019HC WainwrightReiterated RatingBuy$7.00High
9/27/2019William BlairReiterated RatingBuyHigh
9/27/2019HC WainwrightReiterated RatingBuy$7.00High
8/16/2019William BlairReiterated RatingBuyHigh
8/1/2019HC WainwrightReiterated RatingBuy$7.00Low
7/30/2019Robert W. BairdDowngradeOutperform ➝ Neutral$5.00High
6/17/2019HC WainwrightSet TargetBuy$7.00Low
5/23/2019HC WainwrightSet TargetBuy$7.00High
5/13/2019Robert W. BairdInitiated CoverageOutperform ➝ Outperform$5.00High
5/13/2019CowenReiterated RatingBuyHigh
5/10/2019HC WainwrightReiterated RatingBuy$5.00 ➝ $7.00High
3/19/2019HC WainwrightReiterated RatingBuy$5.00Medium
11/11/2018CowenReiterated RatingBuyHigh
11/7/2018HC WainwrightSet TargetBuy$5.00Low
9/4/2018HC WainwrightSet TargetBuy$12.00Low
8/9/2018HC WainwrightSet TargetBuy$12.00High
6/7/2018HC WainwrightSet TargetBuy$12.00Medium
5/10/2018HC WainwrightSet TargetBuy$12.00Low
5/4/2018CowenInitiated CoverageOutperformHigh
3/19/2018Evercore ISIInitiated CoverageOutperform ➝ Outperform$13.00High
3/19/2018Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$12.00High
3/9/2018HC WainwrightReiterated RatingBuy$12.00High
2/9/2018HC WainwrightSet TargetBuy$12.00High
1/17/2018William BlairInitiated CoverageOutperformHigh
1/16/2018HC WainwrightBoost TargetBuy$9.00 ➝ $12.00High
12/20/2017HC WainwrightSet TargetBuy$9.00Low
11/10/2017HC WainwrightReiterated RatingBuy$9.00N/A
10/18/2017HC WainwrightSet TargetBuy$9.00N/A
10/2/2017HC WainwrightSet TargetBuy$9.00Medium
(Data available from 9/28/2017 forward)

News Sentiment Rating

-0.51 (Sell)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
3/2/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/1/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
5/1/2022
  • 0 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 4 very negative mentions
5/31/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
6/30/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
7/30/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 4 very negative mentions
8/29/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
9/28/2022

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Pieris Pharmaceuticals logo
Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin-based drug candidate includes PRS-060/AZD1402, a drug candidate that is in Phase II clinical trial targeting IL-4Ra for the treatment of asthma and other inflammatory diseases; PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis; and immune-oncology program comprises Cinrebafusp alfa, a 4-1BB/ HER2 bispecific for the treatment of HER2-high and HER2-low expressing gastric cancers. The company also develops PRS-344/S095012, a bispecific anticalin-antibody fusion protein targeting 4- 1BB and PD-L1 for immuno-oncology diseases that is in phase 1 clinical trial; and PRS-352, a preclinical-stage program addressing undisclosed targets for immuno-oncology diseases. It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seagen Inc.; and license agreements with Technical University of Munich, Enumeral Biomedical Holdings, Inc., and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. The company also has a clinical trial collaboration and supply agreement with Eli Lilly and Company. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $1.15
Low: $1.11
High: $1.16

50 Day Range

MA: $1.54
Low: $1.11
High: $1.94

52 Week Range

Now: $1.15
Low: $1.10
High: $5.52

Volume

74,095 shs

Average Volume

401,202 shs

Market Capitalization

$85.57 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.06

Frequently Asked Questions

What sell-side analysts currently cover shares of Pieris Pharmaceuticals?

The following Wall Street analysts have issued stock ratings on Pieris Pharmaceuticals in the last year: StockNews.com.
View the latest analyst ratings for PIRS.

What is the current price target for Pieris Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Pieris Pharmaceuticals in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Pieris Pharmaceuticals in the next year.
View the latest price targets for PIRS.

What is the current consensus analyst rating for Pieris Pharmaceuticals?

Pieris Pharmaceuticals currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for PIRS.

What other companies compete with Pieris Pharmaceuticals?

How do I contact Pieris Pharmaceuticals' investor relations team?

Pieris Pharmaceuticals' physical mailing address is 255 State Street 9th Floor, Boston MA, 02109. The biotechnology company's listed phone number is (857) 246-8998 and its investor relations email address is [email protected] The official website for Pieris Pharmaceuticals is www.pieris.com. Learn More about contacing Pieris Pharmaceuticals investor relations.